2X7 Stock Chart & Stats
€19.90
-€0.30(-1.88%)
At close: 4:00 PM EDT
€19.90
-€0.30(-1.88%)
Day’s Range― - ―
52-Week Range€12.30 - €21.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€524.60M
Enterprise Value€518.17
Total Cash (Recent Filing)€45.88M
Total Debt (Recent Filing)€91.59M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Nov 03, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.68
Shares Outstanding26,109,789
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-3.45
Price to Book (P/B)1.20
Price to Sales (P/S)1.76
P/FCF Ratio-26.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€24.26Price Target Upside21.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.06
Revenue Forecast (FY)€231.36M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Market AdoptionSustained double-digit growth and higher guidance indicate continued adoption of pediatric-focused implants, instruments, and specialty products. Expanding procedure volumes and product uptake can deepen surgeon and hospital relationships, supporting durable revenue growth beyond a single reporting period.
High And Improving Gross MarginsGross margins in the low-to-mid 70% range provide substantial economic value from each sale and create room to fund commercial expansion. The latest improvement, driven by higher-margin new products, suggests mix benefits may support margin sustainability as the portfolio develops.
Conservative Balance Sheet And Improving Cash GenerationA meaningful equity base and low relative debt provide financial flexibility while the shift to positive operating cash flow signals improving operating efficiency. If the planned free-cash-flow inflection is achieved, OrthoPediatrics should become less dependent on external funding for growth.
Bears Say
Persistent Net And Operating LossesStrong revenue and gross profit have not yet translated into sustainable GAAP profitability, leaving the company exposed to execution risk as it scales. Continued losses can constrain reinvestment flexibility and weaken the quality of shareholder returns until operating leverage improves.
Free Cash Flow Remains NegativeThe business is not yet consistently self-funding because reinvestment needs and capital spending continue to exceed internally generated cash. Persistent negative free cash flow could increase reliance on available liquidity or borrowing, particularly if the expected 2026 improvement is delayed.
Earnings Exposure To Foreign ExchangeInternational expansion broadens the opportunity set but also exposes reported earnings to currency movements. Foreign-exchange translation and related expenses can obscure underlying operating progress and create recurring volatility in per-share results while overseas sales continue to grow.
OrthoPediatrics News
2X7 FAQ
What was OrthoPediatrics Corp’s price range in the past 12 months?
OrthoPediatrics Corp lowest stock price was €12.30 and its highest was €21.40 in the past 12 months.
What is OrthoPediatrics Corp’s market cap?
OrthoPediatrics Corp’s market cap is €524.60M.
When is OrthoPediatrics Corp’s upcoming earnings report date?
OrthoPediatrics Corp’s upcoming earnings report date is Nov 03, 2026 which is in 33 days.
How were OrthoPediatrics Corp’s earnings last quarter?
OrthoPediatrics Corp released its earnings results on Aug 04, 2026. The company reported -€0.265 earnings per share for the quarter, beating the consensus estimate of -€0.267 by €0.002.
Is OrthoPediatrics Corp overvalued?
According to Wall Street analysts OrthoPediatrics Corp’s price is currently Undervalued.
Does OrthoPediatrics Corp pay dividends?
OrthoPediatrics Corp does not currently pay dividends.
What is OrthoPediatrics Corp’s EPS estimate?
OrthoPediatrics Corp’s EPS estimate is -0.2.
How many shares outstanding does OrthoPediatrics Corp have?
OrthoPediatrics Corp has 26,109,789 shares outstanding.
What happened to OrthoPediatrics Corp’s price movement after its last earnings report?
OrthoPediatrics Corp reported an EPS of -€0.265 in its last earnings report, beating expectations of -€0.267. Following the earnings report the stock price went down -0.568%.
Which hedge fund is a major shareholder of OrthoPediatrics Corp?
Currently, no hedge funds are holding shares in DE:2X7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OrthoPediatrics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€24.26 (21.91% Upside)
€24.26 (21.91% Upside)
Blogger Sentiment
Neutral
DE:2X7 Sentiment 50%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth €41.0M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.55%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
OrthoPediatrics Corp
OrthoPediatrics Corp. is a medical technology firm dedicated to the design, development, and global commercialization of specialized implants and devices. These products are meticulously crafted to be anatomically appropriate for treating children affected by orthopedic conditions across the United States and internationally. The company's diverse offerings span products for trauma and deformity correction, surgical systems for spinal deformities such as scoliosis, and solutions for sports medicine, among others. Their comprehensive product line features items like PediLoc, PediPlates, various cannulated screws, the PediFlex and PediNail systems, PediLoc tibia, advanced anterior cruciate ligament reconstruction systems, specialized locking cannulated blades and proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, the Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and the ApiFix Mid-C system. OrthoPediatrics Corp. primarily serves the pediatric orthopedic market, directly assisting pediatric orthopedic surgeons and caregivers. The company was founded in 2006 and maintains its headquarters in Warsaw, Indiana.
2X7 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial positive momentum: record revenue, record adjusted EBITDA, strong T&D and OPSB growth, material free cash flow improvement, and raised revenue guidance. Challenges were largely timing-related (zero 7D units, Brazil set timing) and temporary foreign exchange headwinds that widened non-GAAP loss per share. Management emphasized disciplined capital allocation and conservatism in guidance while highlighting a multi-year product 'super cycle' that should drive higher-margin, higher-ASP sales over time. On balance, positive operational and financial improvements outweigh the notable but mostly timing- and FX-driven lowlights.View all DE:2X7 earnings summaries2X7 Stock 12 Month Forecast
Average Price Target
€24.26
▲(21.91% Upside)
Technical Analysis
Orthofix Medical
―
Tandem Diabetes Care
―
Varex Imaging
―
Bioventus
―
Treace Medical Concepts
―